Chimeric Antigen by the Fusion of SARS-CoV-2 Receptor Binding Domain with the Extracellular Domain of Human CD154: A Promising Improved Vaccine Candidate

Chimeric Antigen by the Fusion of SARS-CoV-2 Receptor Binding Domain with the Extracellular Domain of Human CD154: A Promising Improved Vaccine Candidate

COVID-19 is a respiratory viral disease caused by a new coronavirus called SARS-CoV-2. This disease has spread rapidly worldwide with a high rate of morbidity and mortality. The receptor-binding domain (RBD) of protein spike (S) mediates the attachment of the virus to the host’s cellular receptor. T...

Full description

Bibliographic Details
Main Authors: Ileanet Ávalos, Thailin Lao, Elsa María Rodríguez, Yasser Zamora, Alianet Rodríguez, Ailyn Ramón, Gilda Lemos, Ania Cabrales, Monica Bequet-Romero, Dionne Casillas, Ivan Andújar, Luis Ariel Espinosa, Luis Javier González, Yanitza Alvarez, Yamila Carpio, Mario Pablo Estrada
Format: Article
Language:English
Published: MDPI AG 2022-06-01
Series:Vaccines
Subjects:
SARS-CoV-2
RBD
HEK-293
lentivirus
vaccine
Online Access:https://www.mdpi.com/2076-393X/10/6/897

Internet

https://www.mdpi.com/2076-393X/10/6/897

Similar Items